BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/16/2024 6:17:54 AM | Browse: 55 | Download: 293
 |
Received |
|
2024-03-23 14:11 |
|
Peer-Review Started |
|
2024-03-23 14:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-05-03 19:39 |
|
Revised |
|
2024-05-14 03:43 |
|
Second Decision |
|
2024-06-14 02:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-06-14 08:09 |
|
Articles in Press |
|
2024-06-14 08:09 |
|
Publication Fee Transferred |
|
2024-06-18 02:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-09 00:24 |
|
Publish the Manuscript Online |
|
2024-07-16 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Naveed Syed, Ashish Vittalrao Chintakuntlawar, Deepti Vilasini, Aisha Mohamed Al Salami, Riad Al Hasan, Imrana Afrooz, Kanishka Uttam Chandani, Ashok Uttam Chandani and Aref Chehal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Naveed Syed, Visiting Professor, Doctor, MBBS, Department of Hematology and Oncology, Sheikh Shakbout Medical City, Mafraq Area, Abu Dhabi 11001, United Arab Emirates. naveed3642003@gmail.com |
| Key Words |
Homologous recombination repair; BRCA1; BRCA2; Homologous recombination deficiency; Ovarian cancer; Breast cancer; Poly (ADP-ribose) polymerase inhibitors; Olaparib; DNA double-strand breaks |
| Core Tip |
Following National Comprehensive Cancer Network guidelines, breast cancer patients were tested for BRCA1/2 mutations, while ovarian cancer patients underwent homologous recombination defect testing. These mutations can be targeted with poly (ADP-ribose) polymerase inhibitor (PARPi) therapy, a form of precision medicine. In this single-center study, we analyzed the proportion of breast and ovarian cancer patients tested for mutations, demographics and disease characteristics of tested patients, and PARPi therapy outcomes. This first-of-its-kind study in the Middle East offers insights into targeted therapy use, contributing to knowledge on PARPis for breast and ovarian cancers. |
| Publish Date |
2024-07-16 06:17 |
| Citation |
<p>Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, Uttam Chandani K, Chandani AU, Chehal A. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients. <i>World J Clin Oncol</i> 2024; 15(7): 848-858</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i7/848.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i7.848 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
